Reshma Kewalramani

2019

In 2019, Reshma Kewalramani earned a total compensation of $6.8M as CEO and President at Vertex Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$1,260,000
Option Awards$1,575,011
Salary$702,308
Stock Awards$3,215,952
Other$63,665
Total$6,816,936

Kewalramani received $3.2M in stock awards, accounting for 47% of the total pay in 2019.

Kewalramani also received $1.3M in non-equity incentive plan, $1.6M in option awards, $702.3K in salary and $63.7K in other compensation.

Rankings

In 2019, Reshma Kewalramani's compensation ranked 1,428th out of 13,971 executives tracked by ExecPay. In other words, Kewalramani earned more than 89.8% of executives.

ClassificationRankingPercentile
All
1,428
out of 13,971
90th
Division
Manufacturing
504
out of 5,701
91st
Major group
Chemicals And Allied Products
153
out of 2,200
93rd
Industry group
Drugs
121
out of 1,886
94th
Industry
Pharmaceutical Preparations
91
out of 1,398
94th
Source: SEC filing on April 28, 2020.

Kewalramani's colleagues

We found six more compensation records of executives who worked with Reshma Kewalramani at Vertex Pharmaceuticals in 2019.

2019

Jeffrey Leiden

Vertex Pharmaceuticals

Chairman

2019

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2019

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Patient Officer

2019

Charles Wagner

Vertex Pharmaceuticals

Chief Financial Officer

2019

Paul Silva

Vertex Pharmaceuticals

SVP & Corporate Controller

2019

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

News

You may also like